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Prevention of canine Leishmania infantum infection is critical to management of 51 
visceral leishmaniasis in people living in endemic areas of Brazil. A bill (PL 1738/11), 52 
currently under consideration, proposes to establish a national vaccination policy 53 
against canine leishmaniasis in Brazil. However, there is no solid scientific evidence 54 
supporting the idea that this could reduce transmission from infected vaccinated dogs to 55 
sand flies to a level that would significantly reduce the risk of L. infantum infection or 56 
visceral leishmaniasis in humans. Thus, we advocate that insecticide-impregnated 57 
collars should be made mandatory for public health purposes and that vaccines are 58 
applied on a case-by-case optional basis for individual dog protection. 59 
 60 















1. Introduction 75 
Brazil is one of the largest foci of human visceral leishmaniasis (VL) caused by 76 
Leishmania infantum, with an annual incidence ranging from 3455 to 4456 cases during 77 
2013–2017 (Ministério da Saúde, 2019). Dogs have been serologically screened and 78 
culled as part of the national VL control programme, which also includes indoor 79 
residual spraying insecticides and human VL treatment (Ministério da Saúde, 2014). 80 
However, this strategy has not apparently led to reductions in either the incidence of 81 
human VL, nor the infection prevalence in dogs, though statistically powered trials to 82 
test these intervention measures are generally lacking (Romero and Boelaert, 2010; 83 
Rocha et al., 2018). 84 
Tools to prevent L. infantum infection or canine leishmaniasis (CanL) in dogs have 85 
been licensed in Brazil, including topical spot-on insecticides and insecticide-86 
impregnated collars, and vaccines. Public reaction to culling pet dogs has also catalysed 87 
recent legislation to now allow veterinarians to treat infected seropositive dogs with 88 
miltefosine as an alternative to euthanasia (Ministério da Agricultura, Pecuária e 89 
Abastecimento and Ministério da Saúde, 2016). 90 
In pursuit of an effective method to reduce VL transmission, a bill (PL 1738/11) to 91 
introduce obligatory annual canine vaccination is currently under Brazilian government-92 
level examination (Câmera dos Deputados, 2019). According to the bill, vaccination 93 
will be mandatory in areas of moderate (annual average of ≥2.4 to 4.4 human VL cases 94 
in the past five years) and intense (≥4.4 human VL cases per year) transmission, but not 95 
in areas of sporadic transmission (≥0.1 to <2.4 human VL cases per year).  96 
Originally proposed in 2011 to prevent CanL, the bill was accepted in 2018 by the 97 
Committee on Social Security and Family and by the Committee on Agriculture, 98 
Livestock, Supply and Rural Development. It is now under analysis by the Committee 99 
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on Finance and Taxation (as of 16th August 2019). If accepted, the bill then will be 100 
assessed for constitutional, legal, juridical and legislative regulations by the Committee 101 
on Constitution, Justice and Citizenship, and scrutinised by the plenary of the Chamber 102 
of Deputies, and/or voted on by the Brazilian Federal Senate.   103 
With such an important decision on the national VL control policy being imminent, 104 
the aim of this paper is to provide a review of the scientific evidence supporting the 105 
proposed vaccination strategy in light of alternative intervention methods, and in so 106 
doing to provide the authors’ informed expert opinion on the bill PL 1738/11. 107 
 108 
2. Licensed CanL vaccines 109 
The vaccine Leishmune® (Zoetis), was licensed in 2003, but the requirements for 110 
research, development, production, evaluation, registration, license renewal, 111 
commercialization, and use of CanL vaccines were amended in 2007 (Ministério da 112 
Agricultura, Pecuária e Abastecimento and Ministério da Saúde, 2007), and this vaccine 113 
was withdrawn from the market in 2014. According to a technical note of the Ministry 114 
of Agriculture, Livestock and Food Supply, Leishmune® did not completely satisfied 115 
the requirements for phase III studies (Ministério da Agricultura, Pecuária e 116 
Abastecimento, 2014). Another vaccine, Leish-Tec® (Ceva Animal Health), was 117 
licensed in 2007 and currently is the only CanL vaccine commercially available in 118 
Brazil. 119 
An effective CanL vaccine should induce strong and long-lasting proinflammatory 120 
(Th1-dominated) immune response in dogs in order to either (i) prevent the 121 
establishment of an initial infection, or (ii) control its progression towards severe 122 
disease and (iii) promote the abrogation of Leishmania transmissibility by vaccinated 123 
dogs if they get infected (Gradoni, 2015). 124 
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The best-case scenario (i) is difficult to achieve by current anti-protozoan vaccines, 125 
despite there is evidence from the field that in endemic areas a proportion of dogs 126 
repeatedly exposed to sand flies potentially infected by L. infantum, never manifest 127 
evidence of infection (i.e. parasite demonstration by microscopy/culture or DNA 128 
amplification from target tissues), while presenting low antibody titres. The strong 129 
refractoriness to infection of these “resistant” dogs might be the result of a particular 130 
immunogenetic background (Soutter et al., 2019) or of natural booster doses determined 131 
by events of defective L. infantum transmission by the vector, as recently seen in a 132 
hamster-sand fly laboratory model (Gradoni et al., 2019). 133 
As for the (ii) scenario, an effective vaccine could represent an important tool for 134 
veterinary care at individual level for dogs exposed to risk of L. infantum infection. A 135 
vaccine-mediated Th1-type immune response will impair parasite multiplication and 136 
dissemination. Increased parasite burden and dissemination are associated with 137 
pathologic immunoglobulin production and immune complex formation in dogs. 138 
On the other hand, scenario (iii), theoretically associated with very good clinical 139 
efficacy of the vaccine, is of key importance as a public health intervention outcome. 140 
Dogs are the most important source of L. infantum infection to sand fly vectors 141 
(Quinnell and Courtenay, 2009). Canine infectiousness, which can only be ascertained 142 
by xenodiagnosis using colonized sand flies, is generally believed to be correlated with 143 
disease progression (Courtenay et al., 2002, 2014), although subclinically infected dogs 144 
(elsewhere defined as “asymptomatic”) were shown to exhibit various degrees of 145 
infectiousness. Unfortunately, CanL studies suffer from a lack of consistency in the 146 
definition of subclinical dogs, which may have brought to contradictive conclusions 147 
(Dantas-Torres et al., 2014). 148 
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Table 1 summarizes the main features of available CanL vaccines, by focusing on the 149 
above scenarios. Leish-Tec® is currently the only vaccine available in Brazil. Other two 150 
vaccines are commercially available in Europe, CaniLeish® (Virbac Animal Health) and 151 
LetiFend® (Laboratorios LETI) licensed by the European Medicine Agency in 2011 and 152 
2017, respectively. Importantly, these vaccines have not been tested for efficacy or 153 
effectiveness against human VL. 154 
 155 
3. Can currently licensed CanL vaccines reduce the risk of infection or VL in 156 
humans? 157 
A study with CaniLeish® revealed that significantly fewer of the sand flies which fed 158 
on the vaccinated dogs were infected when compared to those which fed on the control 159 
dogs (Bongiorno et al., 2013). A previous study conducted in Brazil reported low 160 
transmission rates to sand flies among dogs vaccinated with either Leishmune® or 161 
Leish-Tec® (Fernandes et al., 2014), but a more recent study showed no statistically 162 
significant difference in the general comparison between Leish-Tec®-vaccinated and 163 
placebo dogs (Regina-Silva et al., 2016). Vaccination does partially protect dogs against 164 
development of severe clinical signs (Gradoni, 2015), which are correlated with 165 
infectiousness to sand flies (Courtenay et al., 2014) and therefore could have some 166 
impact on population-level transmission, but theoretically only if dogs 167 
disproportionately contributing to onward transmission are identified and vaccinated. 168 
Mathematical models have suggested that canine vaccination could have a limited to 169 
no effect on the infection incidence in humans, as compared with insecticide-170 
impregnated collars (Sevá et al., 2016; Shimozako et al., 2017; Gomez et al., 2018). 171 
Other simulation studies assessed possible additive effects of Leishmune® or Leish-172 
Tec® vaccination to dog culling in controlling human VL, the former based on data from 173 
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Araçatuba (São Paulo) and Belo Horizonte (Minas Gerais), south-eastern Brazil 174 
(Palatnik-de-Sousa et al., 2009). While this study concluded that Leishmune® 175 
vaccination could increase the efficacy of culling against human VL incidence 176 
(Palatnik-de-Sousa et al., 2009), the Leish-Tec® study suggested that it probably would 177 
not have any additional impact on dog infection rates to protect humans in high-risk 178 
areas (Grimaldi et al., 2017). 179 
In summary, there is no current scientific evidence that canine vaccination 180 
significantly reduces the infectiousness of infected vaccinated dogs. And although there 181 
are no robustly designed community-level field studies to evaluate canine vaccination 182 
efficacy or effectiveness against human infection or VL disease incidence (Romero and 183 
Boelaert, 2010), the existing data suggest that current CanL vaccines need improvement 184 
to warrant a national canine vaccination policy as a public health intervention.  185 
 186 
4. Can insecticide-impregnated collars protect dogs from L. infantum infection and 187 
reduce the risk of human infection and VL? 188 
Three brands of insecticide-impregnated collars to protect dogs against sand fly bites 189 
are available in Brazil, Scalibor® ProtectorBand (MSD Animal Health), and Leevre® 190 
(Ourofino Animal Health), both of which containing 4% deltamethrin, and Seresto® 191 
(Bayer Animal Health), which contains 10% imidacloprid and 4.5% flumethrin. The 192 
collars are designed to reduce the number of sand flies feeding on treated animals and to 193 
increases sand fly mortality (Lucientes, 1999; Halbig et al., 2000; David et al., 2001; 194 
Alves et al., 2015). Considering that the extrinsic incubation period of L. infantum in the 195 
vector is 5–7 days to reach the infective form, these effects reduce the likelihood of a 196 
collared dog acquiring infection and being a source of Leishmania parasites for onward 197 
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transmission. In this way collars are expected to reduce the number of infectious bites 198 
on humans. 199 
Both Scalibor® and Seresto® are efficacious in reducing incident infections in 200 
individual dogs, evidenced by reductions in seroconversion, detection of parasite DNA, 201 
parasite culture or cytology. From the 10 studies of variable design, Scalibor® provides 202 
a median 53.5% (IQR: 49.1%–80.4%; range: 42.4%–100%) protection against canine 203 
seroconversion incidence as tested across endemic regions including Brazil (Oliveira-204 
Lima et al., 2002; Camargo-Neves et al., 2004; Coura-Vital et al., 2018; Kazimoto et 205 
al., 2018; Lopes et al., 2018), North Africa (Aoun et al., 2008), and Middle East 206 
(Gavgani et al., 2002). Of these, the five Brazilian studies report a median 48.3% (IQR: 207 
48.0–53.0%; range: 42.4–69.7%) protective effect against L. infantum infection in dogs. 208 
In one followed-up study of 3,742 seronegative Brazilian dogs, the efficacy of these 209 
collars against infection was 48% estimated by intention-to-treat analysis that included 210 
all recruited dogs, irrespective of collar losses and other non-protocol events (Coura-211 
Vital et al., 2018). The equivalent efficacy estimate by per-protocol analysis which 212 
included only dogs wearing collars continuously and adhering to the study protocol, 213 
increased to 63% (Coura-Vital et al., 2018). 214 
Seresto®, tested less extensively, and exclusively in Italian sheltered dogs, provided a 215 
median level of protection of 93.4% (IQR: 90.9–96.7%; range: 88.3–100%) (Otranto et 216 
al., 2013; Brianti et al., 2014, 2016), which is relatively higher than Scalibor®, as 217 
substantiated by one comparative study of the two collars randomized between dogs. 218 
That study showed Seresto® to prevent 88.3% incident canine infections compared to 219 
61.8% by Scalibor® (Brianti et al., 2016). Moreover, Seresto® provide 8 months of 220 
protection against sand flies, whereas for Scalibor® is labelled for 4 months in Brazil 221 
and 5 months in Europe, though a recent laboratory study demonstrated a sustained anti-222 
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feeding efficacy of >94% for 12 months against Phlebotomus perniciosus (Paulin et al., 223 
2018). As a follow up consequence of this study, the Ministry of Health of Italy 224 
authorized the extension of the label recommendation of Scalibor® for 12 months 225 
(Ministero della Salute, 2018). This extended recommendation is also valid in other 226 
European countries, such as Portugal and Spain (MSD Animal Health, 2019a, 2019b). 227 
From the public health perspective, only two studies have evaluated the protective 228 
effect of the community-wide application of Scalibor® in dogs on the incidence of L. 229 
infantum infection and clinical VL cases in humans, in this case children who are the 230 
high-risk group. Both studies were cluster randomized trial designs involving 231 
community-wide distribution of Scalibor® in hyperendemic villages in Northwest Iran. 232 
In the first study, the authors estimated that the odds of seroconversion was reduced by 233 
43% (95% CLs: 10%, 63%) in ≤10-year-old children (the high-risk group), and by 54% 234 
(95% CLs: 30%, 70%) in dogs (Gavgani et al., 2002). The second study was an 235 
effectiveness trial against clinical VL in the same infant age group conducted in 80 236 
randomly assigned villages, where collars were fitted to dogs prior to four consecutive 237 
transmission seasons. That trial was designed by researchers but implemented by the 238 
local Ministry of Health. At the end of the follow-up period, the relative risk of infantile 239 
VL was 50% (95% CI: 30–82%), with a 48% reduction in the absolute number of 240 
clinical infantile VL cases (Courtenay et al., 2019). 241 
In addition to the epidemiological outcomes in dogs and humans, Scalibor® has been 242 
reported to reduce also domestic sand fly vector densities (Silva et al., 2018), and sand 243 
fly infection prevalence with L. infantum (Kazimoto et al., 2018); both studies were 244 
conducted in Brazil. 245 
We found no peer-reviewed scientific publication on the efficacy of Leevre® in the 246 
international literature. According to a study report available online (Ourofino, 2000), 247 
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this collar works for 6 months, with the repellent efficacy against Lutzomyia 248 
longipalpis, ranging from 81% to 93% and the insecticidal efficacy ranging from 71 to 249 
100%. 250 
 251 
4.1. Intervention objectives 252 
The majority of the collar studies achieved the reported levels of protection within 1–253 
2 transmission seasons, or years, of intervention. However, it is important to recognise 254 
that most studies have collared and monitored outcomes in individual dogs, representing 255 
the degree of protection to be expected by pet owners purchasing and fitting collars to 256 
their owned dogs (e.g. household-level protection). For public health objectives, by 257 
contrast, community-wide collar coverage is required so that the remaining population 258 
benefits from the consequential reductions in transmission (i.e. analogous to providing 259 
herd immunity by community vaccination). One key knowledge gap is the minimum 260 
coverage threshold (percent of total dogs collared) required in any given transmission 261 
intensity setting. For example, in the effectiveness trial in Iran, the mean annual 262 
Scalibor® coverage per village was 87% (95% CI: 84.2–89.0%, range: 65.7–100%), 263 
however changes in human VL incidence attributed to the intervention did not prove to 264 
relate to collar coverage, or indeed any other demographic measure in the studied 265 
villages (Courtenay et al., 2019). Moreover, field studies generally indicate that collars 266 
have been more efficacious in areas where transmission is seasonal (e.g. Italy), as 267 
compared to areas where the transmission occurs all year round (e.g. Brazil) (Otranto 268 
and Dantas-Torres, 2013). 269 
 270 
5. Summary guidelines for preventing Leishmania infantum infection in dogs 271 
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The LeishVet association has published guidelines for the management of CanL 272 
(Solano-Gallego et al., 2011; Miró et al., 2017), with recommendations to help the 273 
veterinary clinician to better understand, diagnose, treat and prevent infection and 274 
disease. LeishVet has been involved in many meetings and discussions on this topic 275 
with veterinarians, human medical professionals, public health regulators from endemic 276 
and non-endemic countries, the pharmaceutical industry and organizations concerned 277 
with the hazard of zoonotic VL. The Brasileish group has also been involved in the 278 
organisation of scientific meetings and guidelines for the management of CanL in Latin 279 
America. Moreover, members of this group have been involved in advisory meetings on 280 
CanL and human VL, organized by public health authorities, including the Pan 281 
American Health Organisation and the Ministry of Health of Brazil. In the following 282 
lines, some major points from the LeishVet and Brasileish guidelines for preventing L. 283 
infantum infection in dogs are summarized: 284 
 285 
 The main way to avoid L. infantum infection is to use topically applied pyrethroids 286 
(i.e. permethrin, deltamethrin or flumethrin) with proven activity against female sand 287 
flies. These products are available in spot-on formulations or in collars and reduce 288 
the risk of new infections in non-infected dogs and the biting of sand flies on already 289 
infected dogs.  290 
 Currently available vaccines do not prevent the establishment of infection and may 291 
allow maintenance of an infected but clinically healthy status in some dogs. The 292 
decision to vaccinate should be based upon individual benefit/risk to the dog, age, 293 
breed, life-style or use, habitat, reproductive status, and owner compliance. 294 
 Immune modulators assessed to date in CanL include domperidone and some dietary 295 
nucleotides in combination with an active hexose correlated compound. 296 
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Domperidone has proven preventative efficacy and dietary nucleotides have been 297 
suggested to reduce disease progression in L. infantum-infected dogs, but more 298 
studies are needed to evaluate the real efficacy of both drugs. In particular, it is 299 
important to assess whether infected dogs treated with these immune modulators 300 
may serve as a source of L. infantum to sand flies (Travi and Miró, 2018). 301 
 Other measures to prevent sand fly bites include: keeping dogs indoors from dusk to 302 
dawn; reducing microhabitats favourable to sand fly breeding in the vicinity of the 303 
house and in other locations where dogs spend time; and indoor house-spraying with 304 
residual insecticides. 305 
 306 
6. Concluding remarks 307 
Controlling CanL in Brazil is not an easy enterprise, owing to the inherent 308 
complexities involved in its transmission cycles in urban and rural settings. For decades, 309 
the public health authorities have attempted to reduce the incidence of VL through the 310 
mass elimination of seropositive dogs, with no apparent success. The available scientific 311 
data support the community-wide use of insecticide-impregnated collars, rather than 312 
vaccination, to reduce the risk of infection in dogs and humans (Gavgani et al., 2002; 313 
Otranto et al., 2013; Brianti et al., 2014, 2016; Paulin et al., 2018; Courtenay et al., 314 
2019). This conclusion is supported by others. In 2015, the European Commission 315 
requested the scientific opinion of the European Food Safety Authority about CanL, 316 
with the objective of mitigating the probability of introduction of the infection into free 317 
areas in the European Union through movements of infected dogs. The Animal Health 318 
and Welfare Panel conducted systematic reviews to evaluate the efficacy of vaccines, 319 
topically applied insecticides and prophylactic medication. The panel members along 320 
with members of a working group on CanL (which includes some of the co-authors of 321 
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the present paper: GB, PB, LG and LSG) concluded that topically applied insecticides 322 
were the most effective mitigation measure to reduce the probability of introduction and 323 
establishment of CanL in free areas (EFSA Panel on Animal Health and Welfare, 2015). 324 
The global expense of vaccination (i.e. three initial doses plus annual booster 325 
vaccination, cold chain, and a range of consumables) and chemotherapeutic treatments 326 
are much higher than applying insecticide-impregnated collars (e.g. two collars per year 327 
for a collar labelled for 6 months of protection). Currently available CanL vaccines are 328 
recommended for use only in seronegative and healthy dogs. So, the costs of pre-testing 329 
add to the cost of vaccination. By contrast, the dog’s infection and health status has 330 
little, if any, influence on the efficacy of insecticide-impregnated collars. 331 
CanL affects disproportionally dogs living in low-income areas in Brazil, as it 332 
happens in most endemic foci in Latin America. Consequently, many dog owners living 333 
in the most affected areas cannot handle the costs of preventive measures. Hence, public 334 
health authorities in Brazil play a pivotal role in delivering health education for dog 335 
owners and promoting tangible actions that could help preventing L. infantum infection 336 
in dogs. Furthermore, even if privately-owned dogs are protected, stray dogs will keep 337 
playing a role as reservoirs of L. infantum and thus a critical role in control campaigns.  338 
Concluding, we agree generally with the actions proposed by the bill 1738/11, but 339 
we strongly suggest to replace the mandatory vaccination of dogs, with the community-340 
wide application of insecticide-impregnated collars. While available vaccines can be 341 
recommended on a case-by-case basis, they should not replace the use of insecticide-342 
impregnated collars because infected vaccinated dogs may still serve as a source of 343 
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